新生血管性年龄相关性黄斑变性眼从布西珠单抗转换为法瑞西单抗的真实世界结局:TRUCKEE研究分析
TRUCKEE研究的事后分析纳入从布西珠单抗转换为法瑞西单抗治疗的新生血管性年龄相关性黄斑变性眼,评估转换后1次和3次注射的解剖与功能结局。转换后1次注射时黄斑中心凹下厚度显著降低(平均-5.25 µm,P = .048),最佳矫正视力与治疗间隔无统计学显著变化;3次注射后各项指标呈数值改善但均未达统计学显著。
要点
- 转换后1次注射法瑞西单抗,黄斑中心凹下厚度平均降低5.25 µm(P = .048)。
- 转换后3次注射,黄斑中心凹下厚度平均降低11.28 µm(P = .086),未达统计学显著。
- 转换后最佳矫正视力和治疗间隔呈数值改善,但均无统计学显著差异。
核心结论
- 从布西珠单抗转换为法瑞西单抗与最佳矫正视力、黄斑中心凹下厚度和再治疗间隔的数值改善相关。
- 作者认为,在已接受布西珠单抗最大程度血管内皮生长因子抑制的患者中观察到的表观获益,可能提示法瑞西单抗抑制血管生成素-2的相关性。
研究设计与样本
- 回顾性、多中心临床队列研究,为TRUCKEE研究的事后分析。
- 134眼(108例患者)从布西珠单抗转换为法瑞西单抗,其中56眼(49例患者)有转换后1次注射法瑞西单抗的完整数据,40眼(34例患者)有转换后3次注射的完整数据。
- 纳入标准为有转换后1次和3次注射法瑞西单抗的解剖和功能结局记录,采用Wilcoxon符号秩检验进行对比分析。
主要发现
- 转换后1次注射法瑞西单抗(平均治疗间隔57.0 ± 32.9天),黄斑中心凹下厚度平均降低5.25 µm(P = .048),最佳矫正视力和治疗间隔变化无统计学显著差异。
- 转换后3次注射法瑞西单抗,与布西珠单抗治疗后相比,黄斑中心凹下厚度平均降低11.28 µm(P = .086),未达统计学显著。
- 转换后3次注射法瑞西单抗,再治疗间隔数值增加5.0天(P = .769),最佳矫正视力数值提高1.63个字母(P = .174),均无统计学显著差异。
- 转换后1次注射时有完整数据的患者平均年龄81.1 ± 7.1岁,其中25例为男性;转换后3次注射时有数据的患者平均年龄80.4 ± 7.7岁,其中16例为男性。
关键数值与推荐
- 主要结局指标为最佳矫正视力(ETDRS字母)、治疗耐久性(治疗间隔天数)和黄斑中心凹下厚度在法瑞西单抗1次和3次注射后的变化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate anatomical and functional outcomes in a subset of eyes with neovascular age-related macular degeneration (nAMD) switched from brolucizumab to faricimab in the real-world TRUCKEE study. DESIGN: Retrospective, multicentric clinical cohort study. SUBJECTS AND PARTICIPANTS: 134 eyes of 108 patients were switched from brolucizumab to faricimab. This study included 56 eyes (49 patients) with complete data after 1 injection of faricimab and 40 eyes (34 patients) with complete data after 3 injections of faricimab. METHODS: A multicenter, retrospective chart review was conducted on real-world participants enrolled in the TRUCKEE study switched from brolucizumab to faricimab for the treatment of nAMD. Participants were considered eligible for this post-hoc analysis if they had documented anatomical and functional outcome data following 1 and 3 injections of faricimab after being switched from brolucizumab. A comparative analysis was performed using the Wilcoxon signed-rank test. MAIN OUTCOME MEASURES: Change in best corrected visual acuity (BCVA) measured in Early Treatment of Diabetic Retinopathy Study (ETDRS) letters, durability - defined as time interval between treatments in days, and central subfield thickness (CST), following 1 and 3 injections of faricimab. RESULTS: The mean age of patients who had complete data after 1 injection of faricimab was 81.1 ± 7.1 years, and 25 were males. After 1 injection of faricimab following the switch, (mean treatment interval of 57.0 ± 32.9 days) a significant reduction in CST was observed (mean -5.25 µm, P = .048). Changes in BCVA and durability were not statistically significant after 1 injection. The mean age of patients who had data after 3 injections was 80.4±7.7 years, and 16 were males. The mean CST reduction measured -11.28 µm, when comparing post-faricimab with post-brolucizumab values (P = .086). Additionally, after 3 injections of faricimab, a numerical increase in retreatment interval (+5.0 days, P = .769) and improvement in visual acuity (BCVA +1.63 letters, P = .174) were observed, though these were not statistically significant. CONCLUSIONS: Switching from brolucizumab to faricimab was associated with numerical improvements in BCVA, CST, and retreatment interval. The apparent benefit in patients already on maximum VEGF suppression with brolucizumab, may suggest the relevance of angiopoetin-2 suppression with faricimab.
引用
- Soylu C, Corradetti G, Alhelaly M, et al. Real-World Outcomes in Eyes With Neovascular AMD Switched From Brolucizumab to Faricimab: A TRUCKEE Study Analysis. Am J Ophthalmol. 2025. PMID: 40816663. doi:10.1016/j.ajo.2025.08.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。